Vanguard Capital Management
KNSA icon

Vanguard Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vanguard Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$87M Buy
1,360,840
+27,747
+2% +$1.44M ﹤0.01% 1624
2026
Q1 		$64.2M Buy
+1,333,093
New +$59.1M ﹤0.01% 1714

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management's KNSA Position: Q2 2026 in Review

Vanguard Capital Management increased its Kiniksa Pharmaceuticals (KNSA) stake by 2.1% in Q2 2026, buying an estimated $1.44M and bringing the position to 1,360,840 shares worth $87M. The position accounts for ﹤0.01% of the portfolio, ranked #1624.

Vanguard Capital Management first reported a position in KNSA in Q1 2026 and has held it in 2 quarters since. 265 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

  • Vanguard Capital Management held 1,360,840 shares of Kiniksa Pharmaceuticals worth $87M as of Q2 2026.
  • Vanguard Capital Management bought 27,747 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $1.44M.
  • Kiniksa Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1624 holding.
  • Vanguard Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 265 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.